Navigation Links
Oral Flu Vaccine On The Horizon In Russia

Russian researchers have developed an intranasal influenza vaccine using a novel adjuvant technology, with plans to develop what could become the first tablet// flu vaccine formulation.

The scientists, from Russia's Influenza Research Institute (RAMS) recently completed a preclinical study on intranasal formulation, with encouraging results. Clinical studies are due to start this autumn, and the vaccine will follow in the footsteps of a rival intranasal flu vaccine, MedImmune's FluMist, which is already on sale in the USA.

The adjuvant used in the vaccine, called Korauban, is an immunostimulant gamma interferon inductor that is closely related to ordinary cellulose. The initial clinical candidate form will include antigens from three inactivated viruses (A1, A2, B). An undisclosed component, permitting 12-month tablet stability, will be used to develop a vaccine in tablet form, said a spokesperson for RAMS.

”The combination of Korauban and vaccine viruses in one preparation leads to a synergy of their action,” said Professor Oleg Kuznetsov, RAMS project manager.

This is displayed in an increase in early synthesis of common interferon, a factor of the synthesis of intensified non-specific resistance of the organism of bacterial and viral infections.”

While adjuvants such as alum have been used in vaccines for decades, there has been interest of late in the development of newer adjuvants that offer more potent or selective immune stimulation. For example, around two-thirds of GlaxoSmithKline's vaccines in development are formulated with new proprietary adjuvant technologies.

Although, FluMist has been on the market since 2003, it remains a minor player compared to injectable flu vaccines, mainly because a requirement to store it frozen makes distribution and administration more complicated. Earlier this month the company won US approval to sell a new formulation that only needs refrigeration, and MedIm mune is hopeful this will kickstart sales. It sold 1.7 million doses of FluMist in the first nine months of 2006, bringing in $18 million in revenues.

Now, the Russian scientists are looking for funding of around $600,000 from investors to develop their technology, although the spokesperson said they may decide to sell it if the right offer is made.

The International Science and Technology Centre (ISTC), a non-profit non-commercial organization based in Moscow, supports the flu project.

Source: Bio-Bio Technology
SI
'"/>




Related medicine news :

1. Vaccine to quit smoking?
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. Vaccine for Alzheimer’s diseas
4. Health Officials Recommend Flu Vaccine
5. Smallpox Vaccine May Help Fight Cervical Cancer
6. Panacea Biotech To Market Anthrax Vaccine
7. New Prostate Cancer Vaccine Shows Promise
8. Drug Firm Offers to Donate Smallpox Vaccine
9. Vaccine guards against shingles
10. Vaccine for septic conditions
11. A new Vaccine for Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... Los Angeles, CA (PRWEB) , ... March 23, 2017 , ... ... half of all Americans, yet poor sleep is likely not the only cause of ... these undesirable characteristics that make you look older or in poor health are likely ...
(Date:3/23/2017)... ... 23, 2017 , ... Corra Group is now offering exclusively ... Verisys through its FACIS and other services maintains the largest healthcare database ... are delighted to be able to offer these various products to our healthcare ...
(Date:3/23/2017)... McKinney, Texas (PRWEB) , ... March 23, 2017 ... ... Operations Command (USSOCOM) awarded Task Force Dagger Foundation the US Special Operations Command’s ... Thomas. During the presentation, General Thomas thanked Task Force Dagger Foundation for its ...
(Date:3/23/2017)... DC (PRWEB) , ... March 23, 2017 , ... News ... Dental Choice has helped score a major victory in Europe for public health and ... , Based on rigorous scientific research and the overwhelming support of European ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... an innovative patient - centric payment system, to expand its focus on patient ... the patient financial experience. , “At Ogden Clinic, we are working to ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 22, 2017 Under ... Chinese pharmaceutical packaging market size increased year by ... From 2017 to 2021, the market size will ... is expected to outnumber RMB140 billion in 2021, ... the rapid development of biological agents and supporting ...
(Date:3/22/2017)... Pennsylvania , 22. März 2017 /PRNewswire/ ... unabhängige und weltweit tätige Anbieter von Produkten ... heute den Erwerb von EPL Archives Inc. ... Stoffe, der Kunden im kompletten Zyklus regulierter ... Verwahrung von Proben, Speicherung von Dokumenten und ...
(Date:3/22/2017)... 22, 2017  Applied BioMath ( www.appliedbiomath.com ), ... research and development, today announced the latest line-up ... 2017 is a day full of presentations, posters, ... (QSP) community. The focus is to learn about ... accelerating drug research and development. The ...
Breaking Medicine Technology: